Invitrogen™ OCT3/4 Recombinant Rat Monoclonal Antibody (EM92), Alexa Fluor™ Plus 488

Description

Alexa Fluor™ Plus recombinant antibodies are conjugated using new, proprietary dye chemistry so you can generate stunning data. Alexa Fluor™ Plus antibodies represent an advancement in fluorescent conjugate technology. Alexa Fluor™ Plus antibodies provide brighter signal compared to leading Alexa Fluor™ antibodies, providing you with better signal-to-noise for your critical experiments. These antibodies show better specificity and lot-to-lot consistency as these are recombinant antibodies, generated by cloning specific genes for the desired antibodies into an expression vector and expressed in vitro. Using conjugate solutions: Centrifuge the protein conjugate solution briefly in a microcentrifuge before use; add only the supernatant to the experiment. This step will help eliminate any protein aggregates that may have formed during storage, thereby reducing nonspecific background staining. Applications Tested: This EM92 antibody has been tested by western blot, Immunocytochemistry and flow cytometry applications analysis of NTERA-2 cells. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 494 nm; Emission: 519 nm; Laser: Blue Laser Filtration: 0.2 μm post-manufacturing filtered.

POU5F1, also commonly known as Oct-4, is a maternally expressed octamer-binding protein that was the first transcription factor described for the early stages of development. The role of POU5F1 in embryonic development suggested that it might be useful in the creation of stem cells that might be useful in cell replacement therapies in the treatment of several degenerative diseases. Artificial stem cells, termed induced pluripotent stem (iPS) cells, can be created by expressing POU5F1 and the transcription factors Sox2, Klf4 and Lin28 along with c-Myc in mouse fibroblasts. More recently, experiments have demonstrated that iPS cells could be generated using expression plasmids expressing POU5F1, Sox2, KlfF4 and c-Myc, eliminating the need for virus introduction, thereby addressing a safety concern for potential use of iPS cells in regenerative medicine.